Semaglutide significantly reduces hyperglycemia, hypertension, and albuminuria in db/db ReninAAV-UNx mice, improving kidney conditions.
With a dose of 30 nmol/kg, semaglutide administration led to reduced glomerulosclerosis severity over 11 weeks.
Assessment using bulk and single-nucleus RNA sequencing identified crucial transcriptome changes linked to immune responses and cellular remodeling processes in the kidneys, specifically in key cell types like macrophages and podocytes. 8 weeks data show that co-administration with lisinopril further enhances renal outcomes, indicating a synergistic therapeutic effect in treating diabetic kidney disease.
Abstract
Introduction Gubra. M. Christensen: Employee; Gubra.